PRPH icon

ProPhase Labs

0.6105 USD
-0.0426
6.52%
At close Dec 20, 4:00 PM EST
After hours
0.6413
+0.0308
5.05%
1 day
-6.52%
5 days
-10.68%
1 month
-20.20%
3 months
-73.91%
6 months
-85.97%
Year to date
-86.84%
1 year
-86.46%
5 years
-69.47%
10 years
-54.78%
 

About: ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Employees: 113

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

20% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 5

0.03% more ownership

Funds ownership: 9.15% [Q2] → 9.18% (+0.03%) [Q3]

7% less funds holding

Funds holding: 29 [Q2] → 27 (-2) [Q3]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

42% less capital invested

Capital invested by funds: $7.29M [Q2] → $4.23M (-$3.05M) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for PRPH.

Financial journalist opinion

Neutral
Seeking Alpha
1 month ago
ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q3 2024 Results Conference Call November 13, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Noella Alexander-Young Welcome to today's presentation. My name is Noella Alexander-Young, Virtual Event Moderator here at Renmark Financial Communications.
ProPhase Labs, Inc. (PRPH) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
ProPhase Labs, Inc. (PRPH) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.30 per share a year ago.
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
1 month ago
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
GARDEN CITY, NY, Nov. 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”), a next generation biotech, genomics and diagnostics company, today announced that they will be presenting third quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on November 13, 2024 at 11:00 AM EST. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
ProPhase Labs Inc. to Present Third Quarter 2024 Financial Results on November 13, 2024
Neutral
GlobeNewsWire
1 month ago
ProPhase Labs Announces Pricing of Public Offering of Common Stock
GARDEN CITY, NY, Nov. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the pricing of its underwritten public offering of 4,170,000 shares of common stock. Each share of common stock is being sold at a public offering price of $0.72 per share, for gross proceeds of approximately $3 million, before deducting underwriting discounts, and offering expenses. All of the shares are being offered by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 625,500 shares of common stock at the public offering price less discounts, to cover over-allotments. The offering is expected to close on November 12, 2024, subject to satisfaction of customary closing conditions.
ProPhase Labs Announces Pricing of Public Offering of Common Stock
Neutral
GlobeNewsWire
2 months ago
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025
Projections for Pharmaloz Manufacturing: Approximately $16-17 Million in Revenue, $6-7 Million in Pre-Tax Earnings for 2025
ProPhase Labs Announces Positive Updates on Strategic Initiatives Company Anticipates Multiple Liquidity Events in H1 2025
Neutral
GlobeNewsWire
3 months ago
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Diamond Equity Research, an equity research firm with a focus on small capitalization public companies has released an Update Note on ProPhase Labs Inc. (NASDAQ: PRPH). The update note includes information on the ProPhase's business model, services, industry, financial results, valuation, and risks and contains our most recent research and analysis of the company.
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)
Neutral
GlobeNewsWire
4 months ago
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event
GARDEN CITY, NY, Aug. 19, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today announced that it will be presenting at the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event
Neutral
Seeking Alpha
4 months ago
ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript
ProPhase Labs, Inc. (NASDAQ:PRPH ) Q2 2024 Earnings Conference Call August 14, 2024 11:00 AM ET Company Participants Noella Alexander-Young - Renmark Financial Communications Ted Karkus - Chief Executive Officer Conference Call Participants Hunter Diamond - Diamond Equity Noella Alexander-Young Hello and good morning, everyone. Welcome to today's presentation.
ProPhase Labs, Inc. (PRPH) Q2 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
4 months ago
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14
GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting second quarter 2024 financial results on a virtual conference call hosted by Renmark Financial on August 14, 2024 at 11:00 am EDT. A press release detailing these results will be issued prior to the virtual conference call. ProPhase Labs Inc. welcomes stakeholders, investors, and other individual followers to register and attend this live event.
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14
Neutral
GlobeNewsWire
5 months ago
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress
PMI Revenues and Earnings Projected to Grow Significantly in the Second Half of 2024 and Full Year 2025. New Strategic Initiatives for PMI Create Significant Opportunities for Liquidity and Value Creation Garden City, NY, July 11, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and diagnostics company, today reported that Pharmaloz Manufacturing, Inc. (“PMI”), its wholly-owned subsidiary, is projecting significant revenues and earnings growth for the second half of 2024 and the entire year of 2025.
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress
Charts implemented using Lightweight Charts™